entertainment -WSS

entertainment

author：focus 2025-09-06 01:59:37 - browse：29599

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Boston competes with Raleigh

WSS

Biogen walks away from Aduhelm, years after polarizing approval

How to pay for weight loss drugs and save Medicare

Biogen walks away from Aduhelm, years after polarizing approval

Syphilis numbers in the United States reach record heights

How generative AI ratchets up security threats for health systems

Medicare Advantage insurers face 0.2% cut to 2025 payments

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Philips to halt sales of sleep apnea machines in U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Pediatric cancer treatments threatened by a new FDA policy

Psychedelics group wrestles with new pharma identity

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Sports medicine is finally prioritizing gender equality

Fetal surgery at risk from Dobbs and new abortion restrictions

Tori Bowie and the unacceptable rates of Black maternal death

With clinical trial data readouts, here's how to spot spin

Wikipedia

Flagship Pioneering launches a new biotech in two countries

Merck, Johnson & Johnson CEOs will testify on high drug prices

Venture capital firm's plans to take over Akron hospital face hurdles

Zyn nicotine pouches become unlikely player in latest culture war

Vertex non

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Wikipedia

focus

hotspot

Wikipedia